Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N6ZP
|
|||
| Former ID |
DIB007884
|
|||
| Drug Name |
SKF-105494
|
|||
| Indication | Diuretic vasodilator [ICD-11: BA00; ICD-10: I10] | Phase 1 | [1], [2], [3] | |
| Company |
SmithKline Beecham plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C54H83N15O10
|
|||
| Canonical SMILES |
CCOC1=CC=C(C=C1)CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CCCC3(CCCCC3)CC(=O)N2)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)N)CC(=O)N)C(C)C)CC4=CC=CC=C4
|
|||
| InChI |
1S/C54H83N15O10/c1-4-79-35-21-19-34(20-22-35)29-39-48(75)67-40(28-33-14-7-5-8-15-33)50(77)69-44(32(2)3)51(78)68-41(30-42(55)70)49(76)66-37(16-11-25-54(31-43(71)63-39)23-9-6-10-24-54)47(74)65-38(18-13-27-62-53(59)60)46(73)64-36(45(56)72)17-12-26-61-52(57)58/h5,7-8,14-15,19-22,32,36-41,44H,4,6,9-13,16-18,23-31H2,1-3H3,(H2,55,70)(H2,56,72)(H,63,71)(H,64,73)(H,65,74)(H,66,76)(H,67,75)(H,68,78)(H,69,77)(H4,57,58,61)(H4,59,60,62)/t36-,37+,38+,39-,40+,41+,44+/m1/s1
|
|||
| InChIKey |
PZEDOGNXHJQAKP-CQRSLYTBSA-N
|
|||
| CAS Number |
CAS 114923-99-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin receptor (VR) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2229). | |||
| REF 2 | Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6. | |||
| REF 3 | Effect of V1/V2-receptor antagonism on renal function and response to vasopressin in conscious dogs. Am J Physiol. 1991 Feb;260(2 Pt 2):F273-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.